Omalizumab and Montelukast Use

    Basic Details
    Date Posted
    Wednesday, February 25, 2015
    Status
    Complete
    Medical Product
    montelukast
    omalizumab
    Description

    Modular program-based one-time assessment of prevalence and incidence of omalizumab and montelukast use among all eligible members and those with several pre-existing condition criteria. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of June 23, 2003 through May 31, 2013. Modular programs are adaptable standardized programs. Results were generated using Modular Program 9, version 3.0; click here for more information. Queries were distributed in March 2014. This report includes data from 18 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    June 23, 2003 - May 31, 2013
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)